ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

EVG Evgen Pharma Plc

0.80
0.00 (0.00%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.80 0.75 0.85 - 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 422k -4.04M -0.0147 -0.54 2.2M
Evgen Pharma Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker EVG. The last closing price for Evgen Pharma was 0.80p. Over the last year, Evgen Pharma shares have traded in a share price range of 0.75p to 4.05p.

Evgen Pharma currently has 274,888,117 shares in issue. The market capitalisation of Evgen Pharma is £2.20 million. Evgen Pharma has a price to earnings ratio (PE ratio) of -0.54.

Evgen Pharma Share Discussion Threads

Showing 6576 to 6599 of 13025 messages
Chat Pages: Latest  269  268  267  266  265  264  263  262  261  260  259  258  Older
DateSubjectAuthorDiscuss
20/1/2021
22:08
Hope they go up for new investors from here but so many and you've been burned I guess. Good luck but I'd rather take the loss and look somewhere like EVG to make those bad losses back as can't see GDR ever getting back to my cost let alone a profit
peanut100
20/1/2021
21:51
No disrespect but I feel you should suggest others on GDR thread buy EVG not us GDR. I had them and took a huge loss and won't look back at that woeful company and CEO. GDR holders may get their losses back here. How can you have a testing kit in Covid times and not sell one unit. Boat and missed springs to mind. They Raised money at huge discount when price went up. EVG holders be aware of this as thats what the broker does for fees.
peanut100
20/1/2021
19:40
Rb. Well spotted. Amateur hour.
bumpa33
20/1/2021
19:38
U should all take a punt on GDR !Risk/reward is massively to upside.Thank me later.
amaretto1
20/1/2021
16:00
Marex are a new mm, they’re making markets in all the retail stuff. They’re ex Cantors. And no, it doesn’t mean a placing 🤦🏼‍♂️
bumpa33
20/1/2021
14:25
At some point the herd will arrive and the rise will be rapid. However, I have absolutely no clue when that will happen as it should have occurred already.....
nobbygnome
20/1/2021
13:49
Well done those who added more today. I was ready to nibble a few more if we had hit 9.5, so did not get my target price.
I have no feel for this company's share price direction whatsoever, but if this turns out to be another false rise, I have some funds aside. A bit top heavy now though, so would rather not have the chance!

lovewinshatelosses
20/1/2021
13:05
Broccoli . . . a breath of fresh air
The importance of eating our greens is impressed on us from an early age. Now a small drug developer on Aim reckons that the humble broccoli may help to stave off some of the breathing problems brought on by Covid-19 and pneumonia.

The Cheshire-based Evgen Pharma is part-way through a mid-stage study of its SFX-01 drug, the active ingredient in which is a synthetic of a compound called sulforaphane, which is found in vegetables such as broccoli, cabbage and kale.


A compound in broccoli is a key ingredient in Evgen Pharma’s SFX-01
GETTY IMAGES
For more than a decade Evgen has been developing the drug as a possible treatment for late-stage breast cancer but bosses think it can be reworked to reduce the severity of acute respiratory distress syndrome in pneumonia and Covid-19 patients.

Scientists believe that SFX-01 can boost the Nrf2 pathway, part of the body’s natural defence against inflammation brought on by viral infections.

So far Evgen has recruited 56 patients to the trial, with the goal to find another 250 or so more people to test the drug on. Data from the first 100 patients is expected to start coming out about April and the study is set to finish later in the year.

The shares closed down ½p, or 3.9 per cent, at 9¾p.

toffeeman
20/1/2021
12:49
No chance toffee - making markets in new small caps and AIM. No reason to raise cash for the minute.
peanut100
20/1/2021
12:38
>>toffee

Yes, that has been mentioned elsewhere. However people often walk on cracks in the pavement without realising that they may fall in to an abyss. They have been warned.

longshanks
20/1/2021
12:08
U still in VAL ?Disappointing share price action there.Been buying here today
amaretto1
20/1/2021
10:55
Any more info on what the Times said about EVG?
on target
20/1/2021
10:54
A company getting a new broker can potentially mean that Toffeeman - maybe that's what you were thinking of?
on target
20/1/2021
10:51
SNG are also one of the companies where they have just started making a market. Pretty sure there isn't a fund raising coming there.....😜
nobbygnome
20/1/2021
10:49
>> toffee

MARX are a new outfit who have recently started creating a market in a whole series of shares. It most definitely does not mean that necessarily...

nobbygnome
20/1/2021
10:47
They have enough cash until end of year according to the CEO's interview last month and their business model is to seek non-dilutive funding to advance the pipeline, and so any near term fund raise would be unlikely imho, unless for a very special material event. Gl :-)
moneymunch
20/1/2021
10:39
MREX, I see 6 on the bid. Looking strong here today.
albert arthur
20/1/2021
10:39
Didn't someone comment elsewhere that the arrival of a new MM is indicative of a possible placing?
toffeeman
20/1/2021
10:26
MARX (the new MM) is now on the bid!
nobbygnome
20/1/2021
10:22
On and UP!!! Gla ..U2 Ng. ;-)
moneymunch
20/1/2021
10:18
Well I would be more than happy to if he stopped making ridiculous over optimistic predictions about company and trial events. As I keep on saying that is ultimately counter productive. Timbo and I know about recruitment to trials and both of us are impressed by the 56 recruited so far. Yet the price went down.....
nobbygnome
20/1/2021
10:12
Seemed like a tiny tree shake yesterday pm... on the back of solid news!!
bocker01
20/1/2021
10:11
Yep a formidable duo!
bocker01
20/1/2021
10:11
You need to team up with Money, Nobby. Boundless energy pulling in the right direction!
bocker01
Chat Pages: Latest  269  268  267  266  265  264  263  262  261  260  259  258  Older

Your Recent History

Delayed Upgrade Clock